PE-backed GTX Medical merges with US peer
PE-backed GTX Medical, a Netherlands-based medtech company, has merged with NeuroRecovery Technologies, a US-based medical devices development company.
The merged entity, GTX Medical BV, will have charitable organisation The Christopher & Dana Reeve Foundation as a new investor, alongside existing investors LSP, Inkef, Wellington Partners and Gimv.
The latter backers invested €26m in a series-A round for GTX in 2016. At the time, the company also secured a €10m deferred innovation loan from the Dutch ministry of Economic Affairs to support the development of its innovative therapeutic solutions.
Company
Founded in December 2014, GTX is developing an implantable neuro-stimulation system with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury. The company is based in Eindhoven and employs around 50 people.
Founded in 2011, NeuroRecovery Technologies is a medical technology company focused on the design and development of devices and applications to help restore function and movement in patients with paralysis. Its current technology evolved from collaborative research between the University of California Los Angeles, the California Institute of Technology, and the University of Louisville. The business is based in San Juan Capistrano.
People
GTX Medical – Sjaak Deckers (CEO).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater